ALK and non-small cell lung carcinoma: In a retrospective study of 89 advanced-NSCLC patients (ALK-positive: 19, EGFR-mutant: 12, KRAS-mutant: 21, and wild type: 37), mPFS was reported as 9 months (95% CI: 3–12) in the ALK-positive, 5.5 months (95% CI: 1–9) in the EGFR mutant, 7 months (95% CI: 1.5–10) in the KRAS mutant, and 4 months (95% CI: 3–5) in the wild type.